Related Experiment Video
Updated: Mar 6, 2026
Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques
Published on: June 1, 2016
Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity
Eva Czirr1, Nicholas A Castello2, Kira I Mosher1
1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Abstract:
Recent genetic evidence supports a link between microglia and the complement system in Alzheimer's disease (AD). In this study, we uncovered a novel role for the microglial complement receptor 3 (CR3) in the regulation of soluble β-amyloid (Aβ) clearance independent of phagocytosis. Unexpectedly, ablation of CR3 in human amyloid precursor protein-transgenic mice results in decreased, rather than increased, Aβ accumulation. In line with these findings, cultured microglia lacking CR3 are more efficient than wild-type cells at degrading extracellular Aβ by secreting enzymatic factors, including tissue plasminogen activator. Furthermore, a small molecule modulator of CR3 reduces soluble Aβ levels and Aβ half-life in brain interstitial fluid (ISF), as measured by in vivo microdialysis. These results suggest that CR3 limits Aβ clearance from the ISF, illustrating a novel role for CR3 and microglia in brain Aβ metabolism and defining a potential new therapeutic target in AD.
Insights
Microglia
Area of Science:
- Neuroscience
- Immunology
- Alzheimer's Disease Research
Background:
- Genetic evidence links microglia and the complement system in Alzheimer's Disease (AD).
- The role of microglial complement receptor 3 (CR3) in amyloid-beta (Aβ) regulation is not fully understood.
Purpose of the Study:
- To investigate the novel role of microglial CR3 in soluble Aβ clearance.
- To explore CR3's impact on Aβ accumulation and degradation in AD models.
Main Methods:
- Utilized human amyloid precursor protein-transgenic mouse models with CR3 ablation.
- Examined Aβ levels in cultured microglia and in vivo using microdialysis.
- Analyzed extracellular Aβ degradation by microglia.
Main Results:
- CR3 ablation in mice led to decreased, not increased, Aβ accumulation.
- CR3-deficient microglia showed enhanced extracellular Aβ degradation via secreted enzymes like tissue plasminogen activator.
- A CR3 modulator reduced soluble Aβ levels and half-life in brain interstitial fluid.
Conclusions:
- Microglial CR3 limits soluble Aβ clearance from brain interstitial fluid, contrary to expectations.
- CR3 plays a novel role in brain Aβ metabolism.
- CR3 represents a potential therapeutic target for Alzheimer's Disease.
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019